Systems and applications for assessing the risk of overall developmental delay in individuals

By detecting specific serum protein biomarkers and combining them with artificial intelligence algorithms, the accuracy and repeatability issues of early identification of comprehensive developmental delay have been resolved. This enables non-invasive and accurate assessment of the risk of comprehensive developmental delay, and is applicable to hospital and children's health follow-up scenarios.

CN122307114APending Publication Date: 2026-06-30FUDAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
FUDAN UNIVERSITY
Filing Date
2026-02-04
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Current technologies lack accurate and objective serum molecular markers for early identification of total developmental delay, and existing screening methods lack intelligent analysis tools based on big data and artificial intelligence technologies, resulting in inaccurate and poor reproducibility of assessment results for total developmental delay.

Method used

An individual global developmental delay risk assessment system based on serum protein biomarkers was adopted. By detecting protein biomarkers encoded by the APOB, CAVIN1, CHIT1, MATR3, RAB7A, FABP5, GSK3B, PSMD8, PTPRA, and SPR genes, combined with a data processing module and artificial intelligence algorithms, the risk of global developmental delay in individuals can be assessed.

Benefits of technology

It provides a non-invasive, highly accurate, and reproducible method for early identification of developmental delay, improving the accuracy and reliability of the assessment. It is applicable to scenarios such as hospital laboratories and children's health follow-up.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122307114A_ABST
    Figure CN122307114A_ABST
Patent Text Reader

Abstract

This invention provides a system and application for assessing the risk of global developmental delay in individuals. The application involves the use of reagents and / or instruments for detecting protein biomarkers in the preparation of products for diagnosing or assisting in the diagnosis of global developmental delay. These protein biomarkers are encoded by the following genes: APOB, CAVIN1, CHIT1, MATR3, RAB7A, FABP5, GSK3B, PSMD8, PTPRA, and SPR. These biomarkers show significant differences in expression among individuals with global developmental delay. Combining high-throughput detection technology and statistical modeling analysis, this system can effectively distinguish between patients with global developmental delay and healthy individuals, enabling risk assessment and auxiliary judgment. This method is non-invasive and safe, and is particularly suitable for early screening scenarios where MRI shows no obvious abnormalities but clinical suspicion is present.
Need to check novelty before this filing date? Find Prior Art